ArticleHemaSphere2021

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.

Graham P Collins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.